Oramed Pharmaceuticals Inc.
ORMP
Rank in Stocks
#17485
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York,... Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
Share Price
$4.00
Last synced: 2026-11-09
Market Cap
$166.39M
Change (1 day)
3.63%
Change (1 year)
65.29%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Oramed Pharmaceuticals Inc. (ORMP)
Category
Healthcare
EPS for Oramed Pharmaceuticals Inc. (ORMP)
EPS as of June 2026 TTM: $4.23
According to Oramed Pharmaceuticals Inc.'s latest financial reports, its current EPS (TTM) is $4.23. At the end of 2025 the company had an EPS of $1.53, an increase over its 2024 EPS of $-0.48.
EPS history for Oramed Pharmaceuticals Inc. from 2003 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $4.23 | 176.47% |
| 2025 | $1.53 | -418.75% |
| 2024 | $-0.48 | -442.86% |
| 2023 | $0.14 | -114.43% |
| 2022 | $-0.97 | 24.36% |
| 2021 | $-0.78 | 39.29% |
| 2020 | $-0.56 | -31.71% |
| 2019 | $-0.82 | -4.65% |
| 2018 | $-0.86 | 8.86% |
| 2017 | $-0.79 | -9.20% |
| 2016 | $-0.87 | 29.85% |
| 2015 | $-0.67 | 8.06% |
| 2014 | $-0.62 | 5.08% |
| 2013 | $-0.59 | 3.51% |
| 2012 | $-0.57 | 96.55% |
| 2011 | $-0.29 | -53.23% |
| 2010 | $-0.62 | 6.90% |
| 2009 | $-0.58 | -14.71% |
| 2008 | $-0.68 | -26.09% |
| 2007 | $-0.92 | 513.33% |
| 2006 | $-0.15 | 2,042.86% |
| 2005 | $-0.01 | -93.64% |
| 2004 | $-0.11 | 2,240.43% |
| 2003 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 270.21% |
US
|
|
| $-7.07 | -267.14% |
US
|
|
| $-5.29 | -225.06% |
AU
|
|
| $12.88 | 204.49% |
BE
|
|
| $21.56 | 409.69% |
NL
|
Questions about Oramed Pharmaceuticals Inc.'s earnings per share (EPS)
What is Oramed Pharmaceuticals Inc.'s earnings per share (EPS)?
Oramed Pharmaceuticals Inc.'s earnings per share (EPS) over the last twelve months is $4.23, as of Jun 2026.
What was Oramed Pharmaceuticals Inc.'s earnings per share (EPS) in 2025?
In 2025, Oramed Pharmaceuticals Inc.'s earnings per share (EPS) was $1.53, compared with $-0.48 in 2024.
How has Oramed Pharmaceuticals Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Oramed Pharmaceuticals Inc.'s earnings per share (EPS) was highest in 2025 ($1.53) and lowest in 2022 ($-0.97).
How does Oramed Pharmaceuticals Inc.'s earnings per share (EPS) compare with similar companies?
Oramed Pharmaceuticals Inc.'s earnings per share (EPS) ($4.23) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.